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Abstract
Background: Cetuximab, an antibody targeting the epidermal growth factor receptor (EGFR), increases survival in 
patients with advanced EGFR-positive non-small cell lung cancer when administrated in combination with 
chemotherapy. In this study, we investigated the role of complement activation in the antitumor mechanism of this 
therapeutic drug.
Results: EGFR-expressing lung cancer cell lines were able to bind cetuximab and initiate complement activation by 
the classical pathway, irrespective of the mutational status of EGFR. This activation led to deposition of complement 
components and increase in complement-mediated cell death. The influence of complement activation on the activity 
of cetuximab in vivo was evaluated in xenografts of A549 lung cancer cells on nude mice. A549 cells express wild-type 
EGFR and have a KRAS mutation. Cetuximab activity against A549 xenografts was highly dependent on complement 
activation, since complement depletion completely abrogated the antitumor efficacy of cetuximab. Moreover, 
cetuximab activity was significantly higher on A549 cells in which a complement inhibitor, factor H, was genetically 
downregulated.
Conclusions: We demonstrate for the first time that the in vivo antitumor activity of cetuximab can be associated with 
a complement-mediated immune response. These results may have important implications for the development of 
new cetuximab-based therapeutic strategies and for the identification of markers that predict clinical response.
Background
Lung cancer accounts for more than 25% of all cancer
deaths in United States [1]. Non-small cell lung cancer
(NSCLC) represents about 80% of all lung cancers. Cur-
rent treatment options consist of surgical resection, plati-
num-based doublet chemotherapy, and radiation.
Unfortunately, despite these therapies, the prognosis
remains poor. Recent advances in the understanding of
the molecular pathogenesis of the disease have led to the
development of molecular targeted therapies for NSCLC
[ 2 ] .  B e v a c i z u m a b ,  a  m o n o c l o n a l  a n t i b o d y  t o  v a s c u l a r
endothelial growth factor, and erlotinib, a small-molecule
tyrosine kinase inhibitor (TKI) of epidermal growth fac-
tor receptor (EGFR), are targeted agents approved in the
treatment of NSCLC [3]. The clinical efficacy of cetux-
imab, a humanized monoclonal antibody against the
extracellular domain of EGFR, has also been evaluated. A
randomized phase III trial has recently shown signifi-
cantly prolonged survival of advanced NSCLC patients
who received cetuximab in combination with platinum-
based chemotherapy as first-line treatment [4]. Con-
versely, combinations of gefitinib or erlotinib, EGFR
tyrosine kinase inhibitors (TKIs), with standard chemo-
therapy in advanced NSCLC have failed to show clinical
benefit [5-8]. Another remarkable observation is that, in
contrast to the evidence for TKI treatment, KRAS muta-
tion status does not appear to be predictive of response to
cetuximab in NSCLC [9-11]. These data strongly suggest
clinically relevant differences between the mechanisms of
action of EGFR-TKIs and cetuximab [12]. In this sense, it
has been suggested that immune mechanisms may con-
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tribute to the antitumor activity of cetuximab [13]. In
particular, cetuximab, alone or in combination with other
antibodies, may elicit immunological responses such as
antibody-dependent cellular cytotoxicity (ADCC) or
complement activation [14-17].
A better understanding of the mechanisms that govern
cetuximab antitumor activity is necessary to optimize its
therapeutic efficacy and to identify those patients who
are going to benefit from the treatment. In the current
report we investigated the influence of the activation of
complement in the action of cetuximab in an in vivo ani-
mal model. We also explored the possibility of enhancing
complement activation in an attempt to increase the clin-
ical efficacy of cetuximab.
Methods
Lung cancer cell lines
A549 (lung adenocarcinoma), HCC827 (lung adenocarci-
noma), and H187 (small-cell lung carcinoma) cell lines
were obtained from the American Type Culture Collec-
tion. Cells were grown in RPMI 1640 supplemented with
10% Fetalclone III (Hyclone), 100 U/ml penicillin, and
100 μg/ml streptomycin.
Sera
Normal human serum (NHS) was used as the source of
complement. A pool of sera from ten healthy donors was
prepared. Heat inactivated NHS (HI-NHS) was obtained
by incubation of the serum at 56°C for 30 minutes.
EGFR mRNA expression
RNA was purified from cells using the Ultraspec Total
RNA Isolation Reagent (Biotecx). RNA was reverse tran-
scribed and the expression of human EGFR mRNA was
analyzed by PCR using the following primers: sense 5'-
GGACGACGTGGTGGATGCCG-3', antisense 5'-
GGCGCCTGTGGGGTCTGAGC-3'. GAPDH was used
as an internal control. Primers for GAPDH mRNA ampli-
fication were: sense 5'-ACTTTGTCAAGCTCATTTCC-
3', antisense 5'-CACAGGGTACTTTATTGATG-3'. PCR
conditions were: 1 cycle of 2 min at 95°C, followed by 30
cycles of 30 sec at 95°C, 30 sec at 55°C, and 30 sec at 72°C,
and finishing with 10 min at 72°C.
KRAS mutations
Human KRAS codon 12 mutations were assessed by
sequencing. Genomic DNA was subjected to PCR ampli-
fication with the following set of intronic primers: sense
5'-CGATACACGTCTGCAGTCAA-3', antisense 5'-
GGTCCTGCACCAGTAATATGC-3'. The PCR prod-
ucts were sequenced using the Big Dye Terminator V1.1
Cycle Sequencing Kit (Applied Biosystems) according to
the protocol supplied by the manufacturer.
C1q fixation
A polystyrene 96-well plate was coated with 30 to 2000 ng
of antibody per well in 100 μl of 50 mM sodium bicarbon-
ate (pH 8.3) during one hour at room temperature. After
washing, the plate was blocked overnight at 4°C with
Tris-buffered saline (TBS) containing 1% bovine serum
albumin, and 0.1% Tween 20. After washing, normal
human serum, used as the source of C1q, was added in
100 μl of veronal buffer [1.8 mM barbital, 3.1 mM barbi-
turic acid, 141 mM sodium chloride, 0.5 mM MgCl2 and
0.15 mM CaCl2 (pH 7.4)] and incubated for 30 min at
37°C. The plate was washed and the assay was developed
with a rabbit anti-human C1q antibody (1:500; Dako), a
goat anti-rabbit antibody coupled to horseradish peroxi-
dase (1:1,000; Sigma-Aldrich) and O-phenylenediamine
dihydrochloride (Sigma-Aldrich). A human IgG1 anti-
body (Sigma-Aldrich) was used as a positive control. The
anti-factor H monoclonal antibody OX24, and heat inac-
tivated NHS (56°C for 30 minutes) were used as negative
c o n t r o l s .  C e t u x i m a b  w a s  k i n d l y  p r o v i d e d  b y  M e r c k
KGaA. OX24 was obtained as previously described [18].
Binding of cetuximab and deposition of complement 
components
C e l l s  w e r e  d e t a c h e d  f r o m  c u l t u r e  d i s h e s  w i t h  t ry p s i n /
EDTA (Lonza), washed once, and resuspended in veronal
buffer. Cells (2 × 105) were mixed and incubated for 15
min at 37°C with NHS (diluted 1:5) and cetuximab (40
μg/ml). After washing, cells were incubated for 30 min at
4°C with the following antibodies: fluorescein isothiocya-
nate (FITC)-conjugated goat anti-human IgG (1:100;
Sigma-Aldrich), rabbit anti-human C1q (1:100; Dako),
FITC-conjugated goat anti-human C3 (1:100, ICN Bio-
medicals), or mouse anti-human C5b-9 (1:100; Dako).
Secondary antibodies were goat anti-rabbit IgG labeled
with Alexa-Fluor 488 (1:100; Invitrogen), or FITC-conju-
gated goat anti-mouse IgG (1:100; Invitrogen). Cells were
analyzed by flow cytometry.
Complement-mediated cell death
Complement-mediated cell death is associated with DNA
fragmentation [19]. DNA fragmentation was evaluated
using a method previously described [20]. In brief, 7 × 105
cells were resuspended in 0.2 ml of RPMI medium con-
taining 30% NHS (or HI-NHS), and treated with 40 μg/ml
of cetuximab for 24 hours at 37°C. Afterwards, cells were
pelleted and fixed in 2 ml of cold 70% ethanol for 60 min
at 4°C. Cells were centrifuged, washed twice with PBS,
resuspended in 0.5 ml of PBS, and incubated with 10 μl of
1 mg/ml RNase A (Sigma) during 1 hour at 37°C. Finally,
5 μl of 1 mg/ml 7-aminoactinomycin D (Sigma) were
added and, after incubation in the dark for 15 min at
room temperature, cells were analyzed by flow cytome-Hsu et al. Molecular Cancer 2010, 9:139
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try. The percentage of DNA giving fluorescence below
the G1/G0 peak was taken as measure of cell death.
Cell proliferation assay
Cells (2,000 A459 cells/well or 4,000 HCC827 cells/well)
were seeded in 96-well plates in RPMI medium supple-
mented with 10% FBS. Twenty-four hours later, cells were
treated with cetuximab at different concentrations, and
incubated for another 24 hours. Ten microliters of MTT
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide) at 5 g/l (Sigma) was added to each well and
incubated for 4 hours at 37°C. Later, 100 μl of dimethyl
sulfoxide was added to each well to dissolve the MTT-for-
mazan crystals. Absorbance was measured at 540 nm,
with a reference filter at 690 nm, using a microplate
reader.
Xenograft model
Care of the animals was in accord with our institution
guidelines. A549 cells (15 × 106) were mixed 1:1 with
Growth Factor Reduced Matrigel Matrix (BD Biosci-
ences), and injected subcutaneously on the right flank of
4-6 week old female athymic nude mice (Harlan Labora-
tories, Italy). Athymic mice are immunodeficient and
cannot develop a complete adaptive immune response,
but have complement and NK cell activities. Tumor
growth was measured every 2-3 days. Tumor volume was
calculated using the formula: Volume = length × width2 ×
0.5. Tumors were allowed to reach about 200-250 mm3
before randomization. When indicated, complement was
depleted with cobra venom factor (CVF), as previously
described [21].
C3 immunofluorescence
X e n o g r a f t s  w e r e  h a rv e s t e d ,  f i x e d  i n  b u f f e r e d  f o r m a l i n ,
paraffin-embedded and sectioned (5 μm thick). Slides
were deparaffinized, blocked with normal rabbit serum
(1:20 dilution), and incubated with a goat anti-mouse C3
(1:500; Santa Cruz Biotechnology). Afterwards, slides
were washed and incubated with a rabbit anti-goat IgG
coupled to Alexa-Fluor 488 (1:500; Invitrogen). Slides
were washed, mounted, and analyzed in an Olympus flu-
orescence microscope.
Statistical analysis
Data were analyzed by Student's t-test. A p value of less
than 0.05 was considered as statistically significant.
Results and Discussion
We used three different lung cancer cell lines in the study:
A549, HCC827, and H187 cells. A549 cells express wild-
type EGFR and have a KRAS mutation (Fig. 1A-B).
HCC827 cells express mutated-EGFR and wild-type
KRAS. H187 cells do not have detectable levels of EGFR.
We first analyzed the capacity of cetuximab to fix com-
plement. C1q from NHS was able to bind to wells coated
with cetuximab (Fig. 2A), but not to wells coated with
OX24, an IgG1 monoclonal antibody unable to fix com-
plement [18]. C1q binding to cetuximab was inhibited by
heat inactivation. We next assessed the capacity of cetux-
imab to fix complement on the membrane of lung cancer
cells. We used 40 μg/ml of cetuximab (at the FDA-
approved dosing level, according to the manufacturer, the
p e a k  a n d  t r o u g h  p l a s m a  c o n c e n t r a t i o n s  o f  c e t u x i m a b
range from 168 to 235 μg/ml and from 41 to 85 μg/ml,
respectively). In cells expressing EGFR, cetuximab treat-
ment initiated complement activation, irrespective of the
mutational status of EGFR (Fig. 2B-C). Complement acti-
vation by the antibody-dependent classical pathway
results in C3b-deposition, which leads to the formation of
the cytolytic C5b-C9 complex [22]. Treatment of EGFR-
expressing cells with cetuximab and NHS led to the depo-
sition of these complement components and to comple-
ment-mediated cell death (Fig. 3A-B). In contrast,
K i m u r a  e t  a l  p r e v i o u s l y  r e p o r t e d  t h a t  c o m p l e m e n t
dependent cytotoxicity was not detected in A549 cells
treated with cetuximab [14], and Dechant et al found that
c o m p l e m e n t  a c t i v a t i o n  o n l y  o c c u r r e d  w h e n  c e t u x i m a b
was combined with other EGFR antibodies [17]. In both
studies cetuximab was used at 10 μg/ml. We confirmed
that there is not complement-mediated cell death with 10
μg/ml of cetuximab, but higher concentrations are
required (data not shown). As mentioned above, the con-
centration used in the present study (40 μg/ml) is similar
to the lowest concentration found in plasma from
patients treated with the standard dosing of cetuximab.
Treatment of EGFR-negative H187 cells with 40 μg/ml of
cetuximab did not affect C3b-deposition, C5b-C9 com-
plex formation, or complement-mediated cell death (Fig.
Figure 1 Characterization of the lung cancer cell lines used in the 
study. A, Expression of EGFR mRNA in A549, HCC827 and H187 cells 
determined by RT-PCR. GAPDH was used as a control. B, Confirmation 
of a KRAS codon 12 mutation (GGT > AGT) in A549 cells.
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Figure 2 Complement fixation by cetuximab. A, C1q binding to cetuximab was first evaluated in wells coated with different amounts of antibody 
and incubated with 1% NHS. A human IgG1 antibody able to fix C1q was used as a positive control. Monoclonal antibody OX24 and heat inactivated 
NHS (HI-NHS) were used as negative controls. Data shows mean ± SEM. B, Flow cytometry analysis of the binding of cetuximab to lung cancer cells 
(black line). A human IgG1 was used as an isotype control (grey line). C, Lung cancer cells were incubated with NHS and cetuximab. The binding of 
C1q to the Fc-region of cetuximab was analyzed by flow cytometry with the anti-human C1q antibody (black line) or an isotype control (grey line). 
Mean fluorescence intensities (MFI) are indicated.
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3C). These results suggest that, upon binding of cetux-
imab to the cell membrane of EGFR -positive cells, the
classical pathway of complement is initiated.
It is important to realize that lysis is not the only biolog-
ical consequence of complement activation in vivo. For
example, complement activation releases anaphylatoxins
that promote proinflammatory responses. In addition,
the interaction of iC3b with CR3 (CD11b/CD18) on
immune cells mediates complement-dependent cellular
cytotoxicity (CDCC). Therefore, cetuximab-mediated
complement activation may generate a powerful antitu-
mor response in an in vivo setting. To test this hypothesis,
we used A549 cells, which express wild-type EGFR and
have a KRAS mutation. In in vitro studies, A549 cells are
insensitive to the blockade of EGFR signaling and resis-
tant to cetuximab [23]. This resistance may be a conse-
quence of the presence of the KRAS mutation. However,
cetuximab has some antitumor effect in vivo in A549
xenografts grown in nude mice [24]. This observation
strongly suggests that cetuximab operates by in vivo
mechanisms of action other than inhibition of EGFR-sig-
naling. We first confirmed the resistance of A549 cells to
cetuximab using an MTT assay (Fig 4A). Afterwards, we
grew A549 xenografts in athymic mice and treated them
with cetuximab. As previously reported [24], tumor
growth was partially inhibited by cetuximab (Fig. 4B).
Interestingly, explanted tumors from mice treated with
cetuximab had high levels of C3 deposition, demonstrat-
Figure 3 Complement activation by cetuximab in lung cancer 
cells. A, Deposition of C3-related fragments and C5b-C9 on A549 cells 
after incubation with NHS and cetuximab was determined by flow cy-
tometry. Incubation with a human IgG1 isotype control was used as 
control. Data were collected as mean fluorescence intensity and the 
graphs show mean + SEM (*, p < 0.05). B and C, Complement-mediat-
ed cell death in A549 (B) and H187 (C) cells treated with cetuximab (40 
μg/ml) and evaluated by flow cytometry. Data were collected as per-
centage of DNA fragmentation and the graph shows mean + SEM (*, P 
< 0.05; n.s., non-significant).
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Figure 4 Complement-dependent antitumor activity of cetux-
imab in A549 xenografts. A, MTT assay for the in vitro antitumor activ-
ity of cetuximab in A549 and HCC827 lung cancer cell lines (with wild-
type and mutant-EGFR, respectively). Cell proliferation was deter-
mined after 24 h treatment using an MTT assay. The graph shows mean 
± SEM. B, A549 cells were injected s.c. on athymic nude mice. When tu-
mors reached 200-250 mm3, mice (n = 10) were randomized into two 
groups: one was treated with cetuximab and the other with PBS. 
Cetuximab was administered i.p. at 0.5 mg per mouse three times a 
week and tumor growth was measured every 2-3 days. Data represent 
mean ± SEM (*, P < 0.05). C, Representative example of the deposition 
of C3-related fragments, determined by immunofluorescence, in ex-
planted tumors from each experimental group. D, A549 xenografts 
were generated as above. Animals (n = 18) were divided into three 
groups. In one group, complement was depleted with CVF. Cetuximab 
treatment was administrated to the CVF-treated group and to a sec-
ond group with full complement activity. The last group received PBS. 
Data represent mean ± SEM (*, P < 0.05).
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ing the capacity of cetuximab to activate complement in
vivo (Fig. 4C). The contribution of complement in the
reduction of tumor growth was confirmed using comple-
ment-deficient mice. Complement depletion was
achieved with cobra venom factor (CVF). Serum C3 lev-
els were reduced to less than 10% as evaluated by ELISA
(data not shown). Complement depletion completely
abrogated the activity of cetuximab in A549 xenografts
(Fig. 4D).
The efficacy of complement-activating antibodies could
be potentiated by the induction of immune effectors sup-
pressed by the tumor microenvironment. In this line, we
tried to increase the efficacy of cetuximab by eliminating
the control exerted by factor H, a complement inhibitor
that prevents an efficient immune response against lung
cancer cells [21]. Incubation of A549 cells with NHS and
cetuximab in the presence of OX24 significantly
increased the deposition of C3-related fragments (Fig.
5A). OX24 is an antibody that inhibits the binding of fac-
tor H to surface-bound C3b. To evaluate the contribution
of factor H to the control of complement-mediated cetux-
imab activity, we used A549 cells in which the expression
of factor H was stably downregulated by siRNA [21]. The
antitumor activity of cetuximab was significantly higher
in factor H-deficient cells than in cells transfected with a
control siRNA (Fig. 5B). Cetuximab-mediated tumor
growth reduction was more than 90% in factor H-defi-
cient cells, compared to around 50% in control cells. In
vivo antitumor activity of cetuximab was again associated
w i t h  a n  i n c r e a s e  i n  t h e  d e p o s i t i o n  o f  C 3 - r e l a t e d  f r a g -
ments (Fig. 5C). In conclusion, these results demonstrate
for the first time that a complement-mediated immune
response induced by cetuximab participates in the con-
trol of tumor cell growth in vivo. This mechanism of
action provides numerous opportunities to enhance the
efficacy of therapeutical monoclonal antibodies [25].
Human tumors in immunocompromised mouse mod-
els do not entirely behave as syngeneic tumors in immu-
nocompetent hosts. For example, although athymic mice
have normal complement activity, they cannot develop an
adequate adaptive immune response. In an intact
immune system, both ADCC and CDCC would likely be
important mediators of cetuximab antitumor activity
(Fig. 6). Thus, the efficacy of cetuximab against human
tumors might be attenuated in our immunocompromised
animal model. Still, our data clearly indicate that comple-
ment activation is sufficient to elicit an intense response
able to induce more than 90%-reduction in the tumor
growth of cells resistant to blockade of the EGFR-signal-
ing pathway. It would be also possible that the activation
of complement may contribute to the antitumor effect of
cetuximab in cells sensitive to the blockade of this path-
way.
It would be interesting to evaluate the immune mecha-
nisms through which complement activation is able to
control tumor growth. A direct effect of complement on
the target cells may be accompanied by the recruitment
and activation of cellular effectors such as lymphokine
activated killer (LAK) cells and natural killer (NK) cells.
In addition, the combination of cetuximab with modifiers
of the immune response may be considered an attractive
therapeutic approach to enhance the clinical efficacy of
cetuximab against lung, colorectal, and head and neck
carcinomas. For example, clinical trials are underway
using cetuximab in combination with β-glucans to treat
colorectal cancer. β-glucans are polysaccharides that col-
laborate with complement-activating antibodies in the
elimination of tumors [26]. Cetuximab may also be com-
bined with other monoclonal antibodies to potentiate
complement activation [17]. Modifications in the Fc-
region of the monoclonal antibody can also be attempted
Figure 5 Effect of factor H downregulation on cetuximab-mediat-
ed complement activation. A, A549 cells were incubated with NHS 
and cetuximab in the presence or absence of OX24, an antibody that 
inhibits the binding of factor H to surface-bound C3b. Deposition of 
C3-related fragments, evaluated by flow cytometry, significantly in-
creased in the presence of OX24 (*, P < 0.05). Data represent mean + 
SEM. B, Xenografts of A549 cells deficient in factor H (FH siRNA) were 
grown in nude mice until they reached ~250 mm3 (n = 8). Half of the 
mice were treated with cetuximab, and the other half with PBS. The 
same experiment was conducted in A549 cells stably transfected with 
a scramble siRNA (control siRNA). Results shown represent mean ± 
SEM. The antitumor activity of cetuximab was significantly higher in 
factor H-deficient cells than in cells transfected with a control siRNA (*, 
P < 0.05). C, representative examples of the deposition of C3-related 
fragments in the explanted tumors.
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to increase the ability of the antibody's activation of com-
plement [27].
In an unselected population, cetuximab treatment, as
many other biological agents, only benefits a small per-
centage of NSCLC patients [28]. The body of knowledge
that has paved the way for more targeted use of cetux-
imab has been recently reviewed [29]. Many groups are
also focusing their research on markers of response (or
resistance) to cetuximab. A more rational use of EGFR-
targeted agents, such as cetuximab, should provide bene-
fits for patients and health-care providers alike by sparing
patients unnecessary treatment and allowing better use of
health-care resources [29]. However, at present, no
molecular biomarker is available to predict response to
cetuximab in NSCLC. Based on our results, polymor-
phisms or other genetic traits that modulate the immune
function may condition the activity of cetuximab, serving
as markers to predict clinical response.
Conclusions
There is a pressing need to elucidate the molecular mech-
anisms involved in cetuximab activity in order to improve
its clinical efficacy and to better select patients who
would benefit from cetuximab treatment. In this paper
we demonstrate that a complement-mediated immune
response participates in the inhibition of tumor cell
growth by cetuximab in vivo. This observation may have
important clinical implications in the development of
new cetuximab-based therapeutic strategies and in the
identification of markers that predict clinical response.
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Figure 6 Effector mechanisms triggered by cetuximab. Cetuximab 
can inhibit EGFR-intracellular signaling or induce an immune response. 
These two antitumor mechanisms may act in conjunction. In certain 
conditions, such as in the presence of KRAS mutations, the immune re-
sponse may be particularly important. The activation of the immune 
system by cetuximab can lead to both antibody-dependent cellular 
cytotoxicity (ADCC) and complement activation. Complement activa-
tion results in complement-dependent cellular cytotoxicity (CDCC) 
and/or complement-dependent cytotoxicity (CDC). CDCC is mediated 
by the interaction of C3b and its receptors in effector cells (e.i. phago-
cytes and NK cells). The release of anaphylatoxins, such as C5a, would 
further increase the recruitment and activation of effector cells. The 
three main immune consequences of complement activation are 
summarized in the boxes.
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